| 2020 |
| 08/21 | 15:00 譲渡制限付株式報酬としての自己株式の処分に関するお知らせ |
| 08/20 | 2,282 | 2,290 | 2,185 | 2,211 | -3.15% | 394,800 | 319億6951万 | -0.45% |
| 08/19 | 2,215 | 2,283 | 2,183 | 2,283 | +3.16% | 324,100 | 330億1058万 | +2.15% |
| 08/18 | 2,160 | 2,224 | 2,130 | 2,213 | +2.5% | 272,300 | 319億9843万 | -1.51% |
| 08/17 | 2,246 | 2,271 | 2,140 | 2,159 | -3.18% | 421,600 | 312億1762万 | -4.6% |
| 08/14 | 2,263 | 2,329 | 2,207 | 2,230 | -1.33% | 547,100 | 322億4423万 | -2.66% |
| 08/13 | 2,186 | 2,283 | 2,163 | 2,260 | +4.48% | 519,600 | 326億7801万 | -2.46% |
| 08/12 | 2,151 | 2,200 | 2,118 | 2,163 | -0.32% | 444,200 | 312億7546万 | -7.6% |
| 08/11 | 2,110 | 2,215 | 2,053 | 2,170 | +5.03% | 647,200 | 313億7668万 | -8.79% |
| 08/07 | 15:00 2020年12月期第2四半期決算短信〔日本基準〕(非連結) |
| 08/07 | 15:00 営業外費用の計上に関するお知らせ |
| 08/07 | 15:00 頭頸部がんを対象としたテロメライシンのPhase2医師主導治験契約に関するお知らせ |
| 08/07 | 2,019 | 2,085 | 2,010 | 2,066 | +1.22% | 440,600 | 298億7291万 | -14.31% |
| 08/06 | 15:00 COVID-19(新型コロナウイルス感染症)治療薬の開発方針について |
| 08/06 | 2,226 | 2,235 | 2,033 | 2,041 | -7.69% | 951,000 | 295億1143万 | -16.86% |
| 08/05 | 2,131 | 2,235 | 2,113 | 2,211 | +3.66% | 631,900 | 319億6951万 | -11.56% |
| 08/04 | 2,086 | 2,172 | 2,076 | 2,133 | +2.25% | 573,200 | 308億4168万 | -16.16% |
| 08/03 | 2,015 | 2,096 | 2,001 | 2,086 | +3.01% | 419,000 | 301億6209万 | -19.49% |
| 07/31 | 2,076 | 2,141 | 2,015 | 2,025 | -3.89% | 755,500 | 292億8008万 | -23.38% |
| 07/30 | 2,076 | 2,132 | 2,018 | 2,107 | +1.01% | 708,600 | 304億6574万 | -21.96% |
| 07/29 | 2,154 | 2,172 | 2,063 | 2,086 | -3.2% | 570,200 | 301億6209万 | -24.12% |
| 07/28 | 2,175 | 2,231 | 2,115 | 2,155 | -1.19% | 562,000 | 311億5979万 | -23.39% |
| 07/27 | 2,326 | 2,330 | 2,176 | 2,181 | -6.95% | 848,200 | 315億3573万 | -23.39% |
| 07/22 | 2,330 | 2,360 | 2,245 | 2,344 | +0.3% | 491,900 | 338億9259万 | -18.04% |
| 07/21 | 2,303 | 2,365 | 2,282 | 2,337 | +1.56% | 590,100 | 337億6100万 | -18.6% |
| 07/20 | 2,308 | 2,350 | 2,230 | 2,301 | -0.73% | 763,400 | 332億4093万 | -19.83% |
| 07/17 | 2,390 | 2,431 | 2,280 | 2,318 | -3.38% | 994,600 | 334億8652万 | -18.78% |
| 07/16 | 2,548 | 2,550 | 2,396 | 2,399 | -5.1% | 1,018,400 | 346億5667万 | -15.68% |
| 07/15 | 2,542 | 2,568 | 2,465 | 2,528 | +0.2% | 669,500 | 362億3711万 | -10.8% |
| 07/14 | 15:00 譲渡制限付株式報酬としての新株式の払込完了に関するお知らせ |
| 07/14 | 2,560 | 2,666 | 2,481 | 2,523 | -1.06% | 1,064,200 | 361億6543万 | -10.69% |
| 07/13 | 2,583 | 2,592 | 2,476 | 2,550 | -1.28% | 753,900 | 365億5246万 | -9.25% |
| 07/10 | 2,620 | 2,707 | 2,525 | 2,583 | -1.41% | 1,175,400 | 370億2549万 | -7.42% |
| 07/09 | 2,855 | 2,881 | 2,611 | 2,620 | -8.55% | 1,747,400 | 375億5586万 | -5.28% |
| 07/08 | 2,886 | 2,939 | 2,793 | 2,865 | -0.24% | 1,036,900 | 410億6776万 | +4.41% |
| 07/07 | 2,762 | 2,906 | 2,760 | 2,872 | +0.35% | 1,259,900 | 411億6810万 | +6.49% |
| 07/06 | 3,025 | 3,040 | 2,806 | 2,862 | -7.97% | 1,713,200 | 410億2476万 | +8% |
| 07/03 | 2,911 | 3,160 | 2,911 | 3,110 | +4.71% | 806,600 | 445億7967万 | +19.52% |
| 07/02 | 3,205 | 3,235 | 2,922 | 2,970 | -6.46% | 1,404,900 | 425億7287万 | +16.79% |
| 07/01 | 15:00 肝細胞がんPhase1企業治験の完了に関するお知らせ |
| 07/01 | 3,190 | 3,275 | 3,120 | 3,175 | +0.16% | 576,900 | 455億1140万 | +27.46% |
| 06/30 | 3,350 | 3,365 | 2,900 | 3,170 | -4.23% | 1,157,500 | 454億3973万 | +30.29% |
| 06/29 | 3,235 | 3,370 | 3,225 | 3,310 | +0.15% | 680,200 | 474億4653万 | +39.72% |
| 06/26 | 3,430 | 3,430 | 3,300 | 3,305 | -2.36% | 756,600 | 473億7486万 | +43.63% |
| 06/25 | 13:30 譲渡制限付株式報酬としての新株式発行に関するお知らせ |
| 06/25 | 3,365 | 3,530 | 3,250 | 3,385 | -1.46% | 2,301,300 | 485億2160万 | +51.45% |
| 06/24 | 3,335 | 3,690 | 3,255 | 3,435 | +3.15% | 3,722,700 | 492億3832万 | +58.73% |
| 06/23 | 3,750 | 3,820 | 3,305 | 3,330 | -10% | 5,680,200 | 477億3321万 | +59.33% |
| 06/22 | 2,964 | 3,700 | 2,961 | 3,700 | +23.33% | 9,481,100 | 530億3691万 | +83.26% |
| 06/19 | 13:00 COVID-19(新型コロナウイルス感染症)治療薬の開発着手について |
| 06/19 | 2,519 | 3,000 | 2,513 | 3,000 | +20% | 1,919,600 | 430億290万 | +55.52% |
| 06/18 | 2,605 | 2,623 | 2,468 | 2,500 | -4.4% | 1,747,700 | 358億3575万 | +34.05% |
| 06/17 | 2,617 | 2,800 | 2,517 | 2,615 | +12.86% | 8,426,200 | 374億8419万 | +43.6% |
| 06/16 | 2,317 | 2,317 | 2,317 | 2,317 | +20.87% | 47,500 | 332億1257万 | +30.61% |
| 06/15 | 15:00 OBP-601の新規ライセンス契約締結のお知らせ |
| 06/15 | 2,077 | 2,184 | 1,900 | 1,917 | -7.66% | 1,107,000 | 274億7885万 | +10.36% |
| 06/12 | 1,982 | 2,114 | 1,956 | 2,076 | -2.31% | 1,511,400 | 297億5800万 | +20.98% |
| 06/11 | 2,263 | 2,298 | 2,100 | 2,125 | -7.77% | 2,075,300 | 304億6038万 | +25.81% |
| 06/10 | 14:30 食道がんを対象とした放射線化学療法併用Phase1医師主導治験契約締結に関するお知らせ |
| 06/10 | 2,074 | 2,450 | 2,040 | 2,304 | +7.26% | 3,766,500 | 330億2622万 | +38.71% |
| 06/09 | 16:00 テロメライシンのハンルイ社との提携解消について |
| 06/09 | 2,050 | 2,177 | 2,007 | 2,148 | +4.93% | 1,883,100 | 307億9007万 | +32.27% |
| 06/08 | 2,099 | 2,100 | 2,003 | 2,047 | +3.07% | 1,396,300 | 293億4231万 | +28.58% |
| 06/05 | 2,018 | 2,160 | 1,967 | 1,986 | -4.79% | 4,637,900 | 284億6791万 | +26.9% |
| 06/04 | 1,992 | 2,086 | 1,941 | 2,086 | +23.72% | 5,838,600 | 299億134万 | +35.63% |
| 06/03 | 16:00 米国FDAによるテロメライシンのオーファンドラッグ指定について |
| 06/03 | 1,700 | 1,702 | 1,633 | 1,686 | -0.24% | 440,700 | 241億6762万 | +11.95% |
| 06/02 | 1,675 | 1,744 | 1,657 | 1,690 | +1.81% | 710,700 | 242億2496万 | +13.27% |
| 06/01 | 1,650 | 1,673 | 1,611 | 1,660 | +0.73% | 400,600 | 237億9493万 | +12.54% |
| 05/29 | 1,650 | 1,681 | 1,626 | 1,648 | -0.12% | 441,600 | 236億2292万 | +12.72% |
| 05/28 | 1,700 | 1,721 | 1,604 | 1,650 | -5.17% | 1,336,900 | 236億5159万 | +13.71% |
| 05/27 | 1,647 | 1,889 | 1,630 | 1,740 | +11.04% | 6,046,500 | 249億4168万 | +21% |
| 05/26 | 1,611 | 1,612 | 1,542 | 1,567 | -2.91% | 464,400 | 224億6184万 | +10.12% |
| 05/25 | 1,662 | 1,673 | 1,606 | 1,614 | -2.18% | 391,800 | 231億3556万 | +14.06% |
| 05/22 | 1,591 | 1,650 | 1,586 | 1,650 | +3.13% | 513,600 | 236億5159万 | +17.35% |
| 05/21 | 1,659 | 1,737 | 1,600 | 1,600 | +0.63% | 1,243,700 | 229億3488万 | +14.86% |
| 05/20 | 1,566 | 1,599 | 1,520 | 1,590 | +2.58% | 685,200 | 227億9153万 | +15.05% |
| 05/19 | 1,490 | 1,594 | 1,451 | 1,550 | +5.95% | 742,500 | 222億1816万 | +12.97% |
| 05/18 | 1,415 | 1,469 | 1,397 | 1,463 | +4.5% | 278,700 | 209億7108万 | +7.49% |
| 05/15 | 1,420 | 1,430 | 1,360 | 1,400 | -0.28% | 269,600 | 200億6802万 | +3.47% |
| 05/14 | 1,433 | 1,476 | 1,392 | 1,404 | -1.68% | 323,800 | 201億2535万 | +4.39% |
| 05/13 | 1,408 | 1,448 | 1,394 | 1,428 | +1.42% | 305,800 | 204億6938万 | +6.89% |
| 05/12 | 1,380 | 1,533 | 1,370 | 1,408 | +2.77% | 850,900 | 201億8269万 | +5.94% |
| 05/11 | 1,381 | 1,400 | 1,330 | 1,370 | -2.7% | 353,400 | 196億3799万 | +3.55% |
| 05/08 | 15:00 2020年12月期第1四半期決算短信〔日本基準〕(非連結) |
| 05/08 | 15:00 営業外費用の計上に関するお知らせ |
| 05/08 | 1,451 | 1,452 | 1,376 | 1,408 | -1.19% | 372,900 | 201億8269万 | +6.67% |
| 05/07 | 1,351 | 1,447 | 1,351 | 1,425 | +3.41% | 391,500 | 204億2637万 | +8.28% |
| 05/01 | 1,341 | 1,388 | 1,312 | 1,378 | +1.7% | 287,900 | 197億5266万 | +5.11% |
| 04/30 | 1,383 | 1,406 | 1,352 | 1,355 | -0.88% | 354,600 | 194億2297万 | +3.44% |
| 04/28 | 1,317 | 1,378 | 1,314 | 1,367 | +3.17% | 230,100 | 195億9498万 | +4.11% |
| 04/27 | 1,299 | 1,339 | 1,278 | 1,325 | +3.11% | 215,400 | 189億9294万 | +0.76% |
| 04/24 | 1,330 | 1,330 | 1,279 | 1,285 | -2.21% | 248,400 | 184億1957万 | -2.5% |
| 04/23 | 1,288 | 1,317 | 1,273 | 1,314 | +3.71% | 240,400 | 188億3527万 | -0.68% |
| 04/22 | 1,340 | 1,340 | 1,264 | 1,267 | -6.01% | 355,200 | 181億6155万 | -4.31% |
| 04/21 | 1,387 | 1,420 | 1,327 | 1,348 | -0.66% | 366,300 | 193億1859万 | +1.51% |
| 04/20 | 1,332 | 1,376 | 1,332 | 1,357 | +0.89% | 156,900 | 194億4757万 | +2.49% |
| 04/17 | 1,357 | 1,370 | 1,326 | 1,345 | -0.88% | 221,300 | 192億7559万 | +1.82% |
| 04/16 | 1,361 | 1,369 | 1,327 | 1,357 | -0.95% | 157,100 | 194億4757万 | +2.96% |
| 04/15 | 1,371 | 1,401 | 1,357 | 1,370 | -1.08% | 221,900 | 196億3388万 | +4.26% |
| 04/14 | 1,344 | 1,415 | 1,336 | 1,385 | +4.92% | 426,600 | 198億4885万 | +5.24% |
| 04/13 | 1,310 | 1,361 | 1,290 | 1,320 | -0.23% | 238,400 | 189億1731万 | +1.15% |
| 04/10 | 1,350 | 1,374 | 1,295 | 1,323 | -2.51% | 248,900 | 189億6030万 | +1.38% |
| 04/09 | 1,271 | 1,374 | 1,261 | 1,357 | +7.19% | 420,500 | 194億4757万 | +3.59% |
| 04/08 | 1,256 | 1,278 | 1,219 | 1,266 | +0.72% | 205,500 | 181億4342万 | -4.09% |
| 04/07 | 1,250 | 1,299 | 1,216 | 1,257 | +3.46% | 336,500 | 180億1444万 | -4.92% |
| 04/06 | 1,168 | 1,237 | 1,160 | 1,215 | +3.23% | 341,800 | 174億1252万 | -8.3% |
| 04/03 | 1,280 | 1,286 | 1,159 | 1,177 | -5.84% | 441,600 | 168億6794万 | -11.04% |
| 04/02 | 1,231 | 1,285 | 1,224 | 1,250 | +0.64% | 270,900 | 179億1412万 | -6.02% |
| 04/01 | 1,300 | 1,313 | 1,231 | 1,242 | -5.34% | 337,200 | 177億9947万 | -7.31% |
| 03/31 | 1,370 | 1,386 | 1,307 | 1,312 | +1.31% | 376,900 | 188億266万 | -3.24% |
| 03/30 | 17:15 次世代テロメライシンOBP-702の開発に向けた助成金採択に関するお知らせ |
| 03/30 | 1,260 | 1,329 | 1,258 | 1,295 | -0.69% | 320,800 | 185億5903万 | -5.61% |
| 03/27 | 1,375 | 1,394 | 1,286 | 1,304 | -4.12% | 599,100 | 186億8801万 | -6.19% |
| 03/26 | 15:00 経営体制に関するお知らせ |
| 03/26 | 1,429 | 1,462 | 1,324 | 1,360 | -5.36% | 502,200 | 194億9056万 | -3.41% |
| 03/25 | 1,448 | 1,505 | 1,409 | 1,437 | +1.34% | 702,900 | 205億9407万 | +1.05% |
| 03/19 | 16:00 海外子会社の設立に関するお知らせ |
